Beauty Health's (SKIN) "Buy" Rating Reiterated at DA Davidson

Beauty Health (NASDAQ:SKIN - Get Free Report)'s stock had its "buy" rating restated by stock analysts at DA Davidson in a research report issued on Monday, Benzinga reports. They currently have a $5.00 price target on the stock. DA Davidson's price target would suggest a potential upside of 82.82% from the company's previous close.

Several other equities research analysts have also recently weighed in on SKIN. Stifel Nicolaus reiterated a "hold" rating and issued a $4.00 price objective (up previously from $3.00) on shares of Beauty Health in a report on Wednesday, March 13th. Piper Sandler dropped their target price on shares of Beauty Health from $3.00 to $2.50 and set an "underweight" rating on the stock in a research note on Friday. Canaccord Genuity Group boosted their price target on Beauty Health from $3.00 to $4.00 and gave the stock a "hold" rating in a research note on Thursday, March 14th. Finally, TD Cowen reduced their price objective on Beauty Health from $4.00 to $3.00 and set a "hold" rating for the company in a report on Monday. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $6.29.

Beauty Health Trading Down 0.2 %

Shares of SKIN traded down $0.01 during mid-day trading on Monday, reaching $2.74. The company's stock had a trading volume of 2,504,105 shares, compared to its average volume of 2,509,616. Beauty Health has a 52 week low of $1.35 and a 52 week high of $10.98. The stock has a market cap of $337.58 million, a PE ratio of -3.91 and a beta of 1.13. The company's fifty day moving average price is $3.68 and its two-hundred day moving average price is $3.26. The company has a current ratio of 6.57, a quick ratio of 5.55 and a debt-to-equity ratio of 10.51.

Beauty Health (NASDAQ:SKIN - Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04. The business had revenue of $81.40 million during the quarter, compared to analyst estimates of $80.56 million. Beauty Health had a negative net margin of 20.48% and a negative return on equity of 0.02%. The company's revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.17) earnings per share. On average, analysts predict that Beauty Health will post -0.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Beauty Health

Several hedge funds have recently modified their holdings of the stock. Kestra Private Wealth Services LLC lifted its position in shares of Beauty Health by 40.8% in the third quarter. Kestra Private Wealth Services LLC now owns 15,887 shares of the company's stock worth $96,000 after buying an additional 4,600 shares in the last quarter. HighMark Wealth Management LLC purchased a new stake in shares of Beauty Health during the 1st quarter worth approximately $31,000. M&T Bank Corp boosted its position in shares of Beauty Health by 6.8% during the 3rd quarter. M&T Bank Corp now owns 125,706 shares of the company's stock valued at $756,000 after acquiring an additional 8,036 shares during the last quarter. Levin Capital Strategies L.P. grew its holdings in shares of Beauty Health by 100.0% in the third quarter. Levin Capital Strategies L.P. now owns 20,000 shares of the company's stock valued at $120,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Raymond James & Associates bought a new stake in Beauty Health in the fourth quarter worth $31,000. Hedge funds and other institutional investors own 93.26% of the company's stock.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.